Molecular alterations of cells resistant to platinum drugs: Role of PKCα

Sabina C. Righetti, Paola Perego, Nives Carenini, Elisabetta Corna, Laura Dal Bo, Sabrina Cedrola, Caterina A M La Porta, Franco Zunino

Research output: Contribution to journalArticle

Abstract

Development of resistance to platinum compounds may involve not only overexpression of defence mechanisms but also alterations in cellular response to the drug-induced genotoxic stress. To investigate the cellular bases of response to platinum compounds, we examined the profile of gene expression of ovarian carcinoma cells exhibiting sensitivity (A2780) or resistance (A2780/BBR3464) to platinum compounds. Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS). This feature was associated with PKCα down-regulation. To explore the role of PKCα in cellular sensitivity to platinum compounds, resistant cells were transfected with a PKCα- containing vector. PKCα-overexpressing resistant cells exhibited a decrease in sensitivity to cisplatin, whereas no significant change in sensitivity to BBR3464 was observed. A number of approaches designed to modulate the function or expression of PKCα support that the isoenzyme may play a role in determining resistance only to cisplatin but not to BBR3464, which is known to activate a different pathway of cell response. In conclusion, in spite of PKCα down-regulation in our model, its regulatory function was not apparently implicated in the development of resistance to platinum compounds and the present results do not support a general role of PKCα as a determinant of the resistance status.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Cell Research
Volume1763
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Platinum
Protein Kinase C
Platinum Compounds
Pharmaceutical Preparations
Cisplatin
Down-Regulation
Transcriptome
Isoenzymes
DNA Damage
Up-Regulation
Carcinoma
Polymerase Chain Reaction
BBR 3464

Keywords

  • Cisplatin
  • Platinum drug
  • Protein kinase C
  • Resistance

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Biophysics

Cite this

Molecular alterations of cells resistant to platinum drugs : Role of PKCα. / Righetti, Sabina C.; Perego, Paola; Carenini, Nives; Corna, Elisabetta; Dal Bo, Laura; Cedrola, Sabrina; La Porta, Caterina A M; Zunino, Franco.

In: Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1763, No. 1, 01.2006, p. 93-100.

Research output: Contribution to journalArticle

Righetti, SC, Perego, P, Carenini, N, Corna, E, Dal Bo, L, Cedrola, S, La Porta, CAM & Zunino, F 2006, 'Molecular alterations of cells resistant to platinum drugs: Role of PKCα', Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1763, no. 1, pp. 93-100. https://doi.org/10.1016/j.bbamcr.2005.12.007
Righetti, Sabina C. ; Perego, Paola ; Carenini, Nives ; Corna, Elisabetta ; Dal Bo, Laura ; Cedrola, Sabrina ; La Porta, Caterina A M ; Zunino, Franco. / Molecular alterations of cells resistant to platinum drugs : Role of PKCα. In: Biochimica et Biophysica Acta - Molecular Cell Research. 2006 ; Vol. 1763, No. 1. pp. 93-100.
@article{0e425467e8394602b2064c856a595e18,
title = "Molecular alterations of cells resistant to platinum drugs: Role of PKCα",
abstract = "Development of resistance to platinum compounds may involve not only overexpression of defence mechanisms but also alterations in cellular response to the drug-induced genotoxic stress. To investigate the cellular bases of response to platinum compounds, we examined the profile of gene expression of ovarian carcinoma cells exhibiting sensitivity (A2780) or resistance (A2780/BBR3464) to platinum compounds. Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS). This feature was associated with PKCα down-regulation. To explore the role of PKCα in cellular sensitivity to platinum compounds, resistant cells were transfected with a PKCα- containing vector. PKCα-overexpressing resistant cells exhibited a decrease in sensitivity to cisplatin, whereas no significant change in sensitivity to BBR3464 was observed. A number of approaches designed to modulate the function or expression of PKCα support that the isoenzyme may play a role in determining resistance only to cisplatin but not to BBR3464, which is known to activate a different pathway of cell response. In conclusion, in spite of PKCα down-regulation in our model, its regulatory function was not apparently implicated in the development of resistance to platinum compounds and the present results do not support a general role of PKCα as a determinant of the resistance status.",
keywords = "Cisplatin, Platinum drug, Protein kinase C, Resistance",
author = "Righetti, {Sabina C.} and Paola Perego and Nives Carenini and Elisabetta Corna and {Dal Bo}, Laura and Sabrina Cedrola and {La Porta}, {Caterina A M} and Franco Zunino",
year = "2006",
month = "1",
doi = "10.1016/j.bbamcr.2005.12.007",
language = "English",
volume = "1763",
pages = "93--100",
journal = "Biochimica et Biophysica Acta - Molecular Cell Research",
issn = "0167-4889",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Molecular alterations of cells resistant to platinum drugs

T2 - Role of PKCα

AU - Righetti, Sabina C.

AU - Perego, Paola

AU - Carenini, Nives

AU - Corna, Elisabetta

AU - Dal Bo, Laura

AU - Cedrola, Sabrina

AU - La Porta, Caterina A M

AU - Zunino, Franco

PY - 2006/1

Y1 - 2006/1

N2 - Development of resistance to platinum compounds may involve not only overexpression of defence mechanisms but also alterations in cellular response to the drug-induced genotoxic stress. To investigate the cellular bases of response to platinum compounds, we examined the profile of gene expression of ovarian carcinoma cells exhibiting sensitivity (A2780) or resistance (A2780/BBR3464) to platinum compounds. Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS). This feature was associated with PKCα down-regulation. To explore the role of PKCα in cellular sensitivity to platinum compounds, resistant cells were transfected with a PKCα- containing vector. PKCα-overexpressing resistant cells exhibited a decrease in sensitivity to cisplatin, whereas no significant change in sensitivity to BBR3464 was observed. A number of approaches designed to modulate the function or expression of PKCα support that the isoenzyme may play a role in determining resistance only to cisplatin but not to BBR3464, which is known to activate a different pathway of cell response. In conclusion, in spite of PKCα down-regulation in our model, its regulatory function was not apparently implicated in the development of resistance to platinum compounds and the present results do not support a general role of PKCα as a determinant of the resistance status.

AB - Development of resistance to platinum compounds may involve not only overexpression of defence mechanisms but also alterations in cellular response to the drug-induced genotoxic stress. To investigate the cellular bases of response to platinum compounds, we examined the profile of gene expression of ovarian carcinoma cells exhibiting sensitivity (A2780) or resistance (A2780/BBR3464) to platinum compounds. Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS). This feature was associated with PKCα down-regulation. To explore the role of PKCα in cellular sensitivity to platinum compounds, resistant cells were transfected with a PKCα- containing vector. PKCα-overexpressing resistant cells exhibited a decrease in sensitivity to cisplatin, whereas no significant change in sensitivity to BBR3464 was observed. A number of approaches designed to modulate the function or expression of PKCα support that the isoenzyme may play a role in determining resistance only to cisplatin but not to BBR3464, which is known to activate a different pathway of cell response. In conclusion, in spite of PKCα down-regulation in our model, its regulatory function was not apparently implicated in the development of resistance to platinum compounds and the present results do not support a general role of PKCα as a determinant of the resistance status.

KW - Cisplatin

KW - Platinum drug

KW - Protein kinase C

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=32144456222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144456222&partnerID=8YFLogxK

U2 - 10.1016/j.bbamcr.2005.12.007

DO - 10.1016/j.bbamcr.2005.12.007

M3 - Article

C2 - 16473140

AN - SCOPUS:32144456222

VL - 1763

SP - 93

EP - 100

JO - Biochimica et Biophysica Acta - Molecular Cell Research

JF - Biochimica et Biophysica Acta - Molecular Cell Research

SN - 0167-4889

IS - 1

ER -